Scarica l'app Stockscreener
71.35
0.88%
0.625
Dopo l'orario di chiusura:
71.35
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$70.72
Aprire:
$71
Volume 24 ore:
818.02K
Relative Volume:
0.77
Capitalizzazione di mercato:
$2.41B
Reddito:
$55.63M
Utile/perdita netta:
$-158.10M
Rapporto P/E:
-8.4737
EPS:
-8.4202
Flusso di cassa netto:
$-203.94M
1 W Prestazione:
+10.04%
1M Prestazione:
+12.10%
6M Prestazione:
+87.62%
1 anno Prestazione:
+185.40%
Intervallo 1D:
$69.67
$73.98
Intervallo di 1 settimana:
$64.24
$73.98
Portata 52W:
$21.02
$109.00
Nektar Therapeutics Stock (NKTR) Company Profile
Nome
Nektar Therapeutics
Settore
Industria
Telefono
(415) 482-5300
Indirizzo
455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO, CA
Compare NKTR vs VRTX, REGN, ARGX, RVMD, ALNY
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NKTR
Nektar Therapeutics
|
71.35 | 2.39B | 55.63M | -158.10M | -203.94M | -8.4202 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Nektar Therapeutics Stock (NKTR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-24 | Iniziato | Wedbush | Neutral |
| 2026-03-17 | Iniziato | TD Cowen | Buy |
| 2026-02-10 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2025-11-26 | Iniziato | Citigroup | Buy |
| 2025-06-24 | Reiterato | BTIG Research | Buy |
| 2025-06-24 | Reiterato | H.C. Wainwright | Buy |
| 2025-04-11 | Aggiornamento | Jefferies | Hold → Buy |
| 2025-03-14 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2025-01-08 | Iniziato | B. Riley Securities | Buy |
| 2024-12-10 | Iniziato | H.C. Wainwright | Buy |
| 2024-11-04 | Iniziato | Piper Sandler | Overweight |
| 2024-09-30 | Ripresa | BTIG Research | Buy |
| 2024-06-28 | Iniziato | Rodman & Renshaw | Buy |
| 2023-11-20 | Ripresa | JP Morgan | Underweight |
| 2023-11-09 | Aggiornamento | TD Cowen | Market Perform → Outperform |
| 2023-05-10 | Aggiornamento | Jefferies | Underperform → Hold |
| 2023-02-24 | Downgrade | Jefferies | Hold → Underperform |
| 2022-08-08 | Downgrade | JP Morgan | Neutral → Underweight |
| 2022-05-31 | Ripresa | Jefferies | Hold |
| 2022-04-18 | Downgrade | Goldman | Neutral → Sell |
| 2022-03-15 | Downgrade | Cowen | Outperform → Market Perform |
| 2022-03-15 | Downgrade | Mizuho | Buy → Neutral |
| 2022-03-14 | Downgrade | BTIG Research | Buy → Neutral |
| 2022-03-14 | Downgrade | BofA Securities | Neutral → Underperform |
| 2022-03-14 | Downgrade | Stifel | Buy → Hold |
| 2022-03-14 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2022-03-09 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2021-11-08 | Aggiornamento | The Benchmark Company | Hold → Buy |
| 2021-09-10 | Iniziato | BofA Securities | Neutral |
| 2021-06-28 | Aggiornamento | Stifel | Hold → Buy |
| 2021-05-18 | Ripresa | Goldman | Neutral |
| 2021-02-22 | Downgrade | The Benchmark Company | Buy → Hold |
| 2021-01-06 | Iniziato | Stifel | Hold |
| 2020-09-14 | Iniziato | JP Morgan | Neutral |
| 2020-06-10 | Downgrade | CFRA | Hold → Sell |
| 2020-05-12 | Reiterato | H.C. Wainwright | Neutral |
| 2020-04-22 | Iniziato | The Benchmark Company | Buy |
| 2020-03-30 | Aggiornamento | Goldman | Sell → Neutral |
| 2020-03-04 | Iniziato | Barclays | Overweight |
| 2020-02-03 | Aggiornamento | Mizuho | Neutral → Buy |
| 2019-10-24 | Iniziato | Oppenheimer | Perform |
| 2019-10-08 | Downgrade | Goldman | Buy → Sell |
| 2019-08-09 | Downgrade | JP Morgan | Overweight → Neutral |
| 2019-08-09 | Downgrade | Jefferies | Buy → Hold |
| 2019-08-09 | Downgrade | Mizuho | Buy → Neutral |
| 2019-03-15 | Iniziato | SVB Leerink | Mkt Perform |
| 2018-12-13 | Iniziato | Goldman | Buy |
| 2018-06-11 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2018-06-04 | Reiterato | H.C. Wainwright | Buy |
| 2018-04-20 | Iniziato | Seaport Global Securities | Buy |
| 2018-04-13 | Ripresa | Piper Jaffray | Overweight |
| 2018-04-06 | Reiterato | Mizuho | Buy |
| 2018-04-02 | Ripresa | H.C. Wainwright | Buy |
Mostra tutto
Nektar Therapeutics Borsa (NKTR) Ultime notizie
Is Nektar Therapeutics (NKTR) Undervalued On Its Phase 3 Rezpegaldesleukin Launch? - simplywall.st
Nektar: Sanofi’s Exit Clears A Competitor But Raises The Bar In Atopic Dermatitis (NKTR) - Seeking Alpha
Nektar Therapeutics (NKTR) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Bronstein, Gewirtz & Grossman, LLC Is Investigating Nektar Therapeutics (NKTR) And Encourages Stockholders to Connect - ACCESS Newswire
Nektar Therapeutics (NKTR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Nektar Therapeutics (NKTR) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
NKTR|Nektar Therapeutics|Price:70.004|Chg%:-0.721 - TradingKey
Nektar Therapeutics (NKTR) Valuation: PE, PB & Fair Value Analysis - TradingKey
Form 4 Nektar Therapeutics For: 24 July By Investing.com - Investing.com Nigeria
Nektar Therapeutics (NKTR) CEO granted 57,200 options with $15.15 strike - Stock Titan
Nektar Therapeutics Reports Vesting of 16,500 Stock Options for Chief R&D Officer Jonathan Zalevsky - Kalkine Media
Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - TradingView
Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - PR Newswire
How Investors Are Reacting To Nektar Therapeutics (NKTR) Launching Global Phase 3 ZENITH AD Trials - simplywall.st
ITH0.F interactive stock chart | Nektar Therapeutics R stock - Yahoo Finance UK
Analysts Offer Insights on Healthcare Companies: Johnson & Johnson (JNJ), Helus Pharma (HELP) and Nektar Therapeutics (NKTR) - The Globe and Mail
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Nektar Therapeutics (NKTR) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
NKTR Stock Soars After Nektar Reports Positive Atopic Dermatitis Trial Results - Stocktwits
symbol__ Stock Quote Price and Forecast - CNN
NKTR|Nektar Therapeutics|Price:70.780|Chg%:+1.420 - TradingKey
Nektar Therapeutics Initiated at Buy by Canaccord Genuity - Moomoo
NKTR Up on Start of Phase III Program on Rezpeg for Atopic Dermatitis - Yahoo Finance
Nektar Therapeutics (NKTR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Nektar (NKTR) Launches Global Trials for Novel Atopic Dermatitis Treatment - GuruFocus
Nektar Therapeutics Starts Phase 3 ZENITH AD Program Evaluating Rezpegaldesleukin in Moderate-to-Severe AD - The Dermatology Digest
Nektar Therapeutics Announces Start of Phase 3 ZENITH AD Program Evaluating Novel Regulatory T-Cell Biologic Rezpegaldesleukin in Moderate-to-Severe Atopic Dermatitis - PR Newswire
Bronstein, Gewirtz & Grossman, LLC Encourages Nektar Therapeutics (NKTR) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
Enterprise value to EBIT forward of Nektar Therapeutics – BMV:NKTR - TradingView
Nektar Therapeutics (NKTR) Stock Looks Above Fair Value Despite Its 7x Run - simplywall.st
Enterprise value to EBITDA forward of Nektar Therapeutics – BMV:NKTR - TradingView
Price to sales forward of Nektar Therapeutics – BMV:NKTR - TradingView
Bronstein, Gewirtz & Grossman, LLC Is Investigating Nektar Therapeutics (NKTR) And Encourages Shareholders to Connect - ACCESS Newswire
ETFs Investing in Nektar Therapeutics Stocks - TradingView
Enterprise value to EBIT forward of Nektar Therapeutics – MUN:ITH0 - TradingView
Bronstein, Gewirtz & Grossman, LLC Is Investigating Nektar Therapeutics (NKTR) And Encourages Investors to Connect - ACCESS Newswire
2026-07-16 | Bronstein, Gewirtz & Grossman, LLC Is Investigating Nektar Therapeutics (NKTR) And Encourages Shareholders to Connect | NDAQ:NKTR | Press Release - Stockhouse
Nektar Therapeutics (NKTR) Investigation: Bronstein, Gewirtz & Gr - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Encourages Nektar Therapeutics - The National Law Review
BTIG Maintains Nektar Therapeutics(NKTR.US) With Buy Rating, Maintains Target Price $178 - 富途牛牛
Q32 bounces back to claim study success for alopecia drug - BioPharma Dive
Bronstein, Gewirtz & Grossman, LLC Encourages Nektar Therapeutics (NKTR) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
2026-07-12 | Bronstein, Gewirtz & Grossman, LLC Encourages Nektar Therapeutics (NKTR) Stockholders to Inquire about Securities Investigation | NDAQ:NKTR | Press Release - Stockhouse
Does Nektar Therapeutics (NKTR) Straddling Russell Growth and Value Indexes Reveal a Conflicted Narrative? - Sahm
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Nektar Therapeutics (NKTR) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Nektar Therapeutics (NKTR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Enterprise value to EBITDA forward of Nektar Therapeutics – LSE:0UNL - TradingView
Analysts Offer Insights on Healthcare Companies: Pyxis Oncology (PYXS) and Nektar Therapeutics (NKTR) - The Globe and Mail
Nektar Therapeutics (NKTR) Advances Autoimmune Pipeline, Is The Upside Already Priced In? - simplywall.st
NKTR Stock Clocks Best Day In Over 2 Months As Investors Await Upcoming Clinical Data In Eczema - Stocktwits
Insider Sell: Jonathan Zalevsky Sells Shares of Nektar Therapeutics (NKTR) - GuruFocus
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Nektar Therapeutics (NKTR) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
Nektar Therapeutics Azioni (NKTR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.97%
0.83%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):